IONS Relative Valuation
IONS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IONS is overvalued; if below, it's undervalued.
Historical Valuation
Ionis Pharmaceuticals Inc (IONS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -25.45. The fair price of Ionis Pharmaceuticals Inc (IONS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：81.84
Fair
-30.11
PE
1Y
3Y
5Y
Trailing
Forward
-21.83
EV/EBITDA
Ionis Pharmaceuticals Inc. (IONS) has a current EV/EBITDA of -21.83. The 5-year average EV/EBITDA is -16.37. The thresholds are as follows: Strongly Undervalued below -34.78, Undervalued between -34.78 and -25.57, Fairly Valued between -7.16 and -25.57, Overvalued between -7.16 and 2.05, and Strongly Overvalued above 2.05. The current Forward EV/EBITDA of -21.83 falls within the Historic Trend Line -Fairly Valued range.
-23.04
EV/EBIT
Ionis Pharmaceuticals Inc. (IONS) has a current EV/EBIT of -23.04. The 5-year average EV/EBIT is -14.66. The thresholds are as follows: Strongly Undervalued below -51.86, Undervalued between -51.86 and -33.26, Fairly Valued between 3.94 and -33.26, Overvalued between 3.94 and 22.54, and Strongly Overvalued above 22.54. The current Forward EV/EBIT of -23.04 falls within the Historic Trend Line -Fairly Valued range.
17.08
PS
Ionis Pharmaceuticals Inc. (IONS) has a current PS of 17.08. The 5-year average PS is 9.54. The thresholds are as follows: Strongly Undervalued below 5.36, Undervalued between 5.36 and 7.45, Fairly Valued between 11.62 and 7.45, Overvalued between 11.62 and 13.71, and Strongly Overvalued above 13.71. The current Forward PS of 17.08 falls within the Strongly Overvalued range.
-46.87
P/OCF
Ionis Pharmaceuticals Inc. (IONS) has a current P/OCF of -46.87. The 5-year average P/OCF is -24.67. The thresholds are as follows: Strongly Undervalued below -56.99, Undervalued between -56.99 and -40.83, Fairly Valued between -8.51 and -40.83, Overvalued between -8.51 and 7.65, and Strongly Overvalued above 7.65. The current Forward P/OCF of -46.87 falls within the Undervalued range.
-31.59
P/FCF
Ionis Pharmaceuticals Inc. (IONS) has a current P/FCF of -31.59. The 5-year average P/FCF is -213.80. The thresholds are as follows: Strongly Undervalued below -1906.06, Undervalued between -1906.06 and -1059.93, Fairly Valued between 632.34 and -1059.93, Overvalued between 632.34 and 1478.47, and Strongly Overvalued above 1478.47. The current Forward P/FCF of -31.59 falls within the Historic Trend Line -Fairly Valued range.
Ionis Pharmaceuticals Inc (IONS) has a current Price-to-Book (P/B) ratio of 21.34. Compared to its 3-year average P/B ratio of 15.10 , the current P/B ratio is approximately 41.30% higher. Relative to its 5-year average P/B ratio of 12.46, the current P/B ratio is about 71.22% higher. Ionis Pharmaceuticals Inc (IONS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.29%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.71% , the current FCF yield is about -100.00% lower.
21.33
P/B
Median3y
15.10
Median5y
12.46
-2.28
FCF Yield
Median3y
-6.29
Median5y
-3.71
Competitors Valuation Multiple
The average P/S ratio for IONS's competitors is , providing a benchmark for relative valuation. Ionis Pharmaceuticals Inc Corp (IONS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 17.12%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IONS increased by 134.01% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -21.24 to -50.71.
The secondary factor is the Revenue Growth, contributed 17.12%to the performance.
Overall, the performance of IONS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Ionis Pharmaceuticals Inc (IONS) currently overvalued or undervalued?
What is Ionis Pharmaceuticals Inc (IONS) fair value?
How does IONS's valuation metrics compare to the industry average?
What is the current P/B ratio for Ionis Pharmaceuticals Inc (IONS) as of Dec 05 2025?
What is the current FCF Yield for Ionis Pharmaceuticals Inc (IONS) as of Dec 05 2025?
What is the current Forward P/E ratio for Ionis Pharmaceuticals Inc (IONS) as of Dec 05 2025?